Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 7/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30373640 | 1.00 | CRBN (0.57) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL26470350 | 0.96 | CRBN (0.55) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL30373512 | 0.96 | CRBN (0.55) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL26469968 | 0.96 | CRBN (0.54) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL26474350 | 0.96 | CRBN (0.54) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL26132855 | 0.94 | CRBN (0.53) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL26133693 | 0.93 | CRBN (0.52) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL30373437 | 0.93 | CRBN (0.53) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL26472335 | 0.93 | CRBN (0.53) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL30373678 | 0.92 | CRBN (0.52) | CRBNGSPT1DDB1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069720-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |